Cargando…

PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia

This study explored the novel immune checkpoint poliovirus receptor- related immunoglobulin domain-containing (PVRIG) in acute myeloid leukemia (AML). We showed that AML patient blasts consistently expressed the PVRIG ligand (poliovirus receptor-related 2, PVRL2). Furthermore, PVRIG blockade signifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jessica, Whelan, Sarah, Kotturi, Maya F., Meyran, Deborah, D’Souza, Criselle, Hansen, Kyle, Liang, Spencer, Hunter, John, Trapani, Joseph A., Neeson, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634199/ https://www.ncbi.nlm.nih.gov/pubmed/33147937 http://dx.doi.org/10.3324/haematol.2020.258574

Ejemplares similares

DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
por: Sanchez-Correa, Beatriz, et al.
Publicado: (2019)

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells
por: Richardson, Kelden, et al.
Publicado: (2022)

Myeloma natural killer cells are exhausted and have impaired regulation of activation
por: D’Souza, Criselle, et al.
Publicado: (2021)

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
por: Li, Yangyang, et al.
Publicado: (2021)

Prognostically relevant natural killer cell-mediated immunoediting in acute myeloid leukemia
por: Chan, Christopher J, et al.
Publicado: (2013)

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
por: D'Souza, Criselle, et al.
Publicado: (2021)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

BSBM-15 SYSTEMIC AND LOCAL IMMUNE RESPONSES FOLLOWING STEREOTACTIC RADIOSURGERY TO BRAIN METASTASES FROM HER2-AMPLIFIED BREAST CANCER
por: Sia, Joseph, et al.
Publicado: (2023)

CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
por: Qin, Vicky Mengfei, et al.
Publicado: (2022)

Combining chemotherapy with CAR-T cell therapy in treating solid tumors
por: Wang, Arthur Xuan, et al.
Publicado: (2023)

The role of natural killer cells in chronic myeloid leukemia
por: Danier, Anna Carolyna Araújo, et al.
Publicado: (2011)

Natural killer cell-based immunotherapy for acute myeloid leukemia
por: Xu, Jing, et al.
Publicado: (2020)

Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia
por: Jamal, Esraa, et al.
Publicado: (2020)

Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
por: Fleuren, Emmy D. G., et al.
Publicado: (2021)

The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
por: Parisi, Sarah, et al.
Publicado: (2017)

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
por: Giannopoulos, Krzysztof
Publicado: (2019)

Expression patterns of immune checkpoints in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2020)

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
por: Martner, Anna, et al.
Publicado: (2015)

Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells
por: Dulphy, Nicolas, et al.
Publicado: (2016)

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
por: Chretien, Anne-Sophie, et al.
Publicado: (2017)

Acute Myeloid Leukemia Epigenetic Immune Escape From Nature Killer Cells by ICAM-1
por: Xiao, Yang, et al.
Publicado: (2021)

Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cianga, Vlad Andrei, et al.
Publicado: (2021)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Macrophages protect mycoplasma‐infected chronic myeloid leukemia cells from natural killer cell killing
por: Choo, Qing Wei Winnie, et al.
Publicado: (2020)

Secreted β(3)-Integrin Enhances Natural Killer Cell Activity against Acute Myeloid Leukemia Cells
por: Skaik, Younis, et al.
Publicado: (2014)

Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy
por: Ruggeri, Loredana, et al.
Publicado: (2015)

Sjögren's Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature
por: Feng, Hao, et al.
Publicado: (2016)

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
por: Kulkarni, Uday, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis
por: Gómez-Llobell, Marina, et al.
Publicado: (2022)

Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia
por: Wu, Yuyan, et al.
Publicado: (2023)

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
por: Nguyen, Rosa, et al.
Publicado: (2019)

Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma
por: Terry, Rachael L., et al.
Publicado: (2021)

Natural Killer Cell-Mediated Immunotherapy for Leukemia
por: Allison, Michaela, et al.
Publicado: (2022)

Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
por: Dai, Yu-Jun, et al.
Publicado: (2021)

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
por: Truxova, Iva, et al.
Publicado: (2020)

Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia
por: Park, Soojin, et al.
Publicado: (2021)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8r5f4uv732r18u6cmvc6jeg7mr